Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company (Industry)
Overall Status
Available ID

Study Details

Study Description

Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Condition or DiseaseIntervention/TreatmentPhase

Study Design

Study Type:
Expanded Access
Official Title:
Master Rollover Protocol for Continued Safety Assessment of Study Drug

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Inclusion Criteria:
    • To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.
    Exclusion Criteria:
    • Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

    Contacts and Locations


    SiteCityStateCountryPostal Code
    1UCLA Medical CenterTorranceCaliforniaUnited States90505
    2Fort Wayne Oncology & HematologyFort WayneIndianaUnited States46804
    3Sarah Cannon Cancer CenterNashvilleTennesseeUnited States37203

    Sponsors and Collaborators

    • Eli Lilly and Company


    • Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT -5 hours, EST), Eli Lilly and Company

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Eli Lilly and Company Identifier:
    Other Study ID Numbers:
    • 16161
    • I8I-MC-JYAA
    First Posted:
    Dec 17, 2015
    Last Update Posted:
    Nov 18, 2021
    Last Verified:
    Nov 15, 2021

    Study Results

    No Results Posted as of Nov 18, 2021